Detailed Narrative
NERLYNX Commercial Performance
Puma reported strong Q2 FY26 NERLYNX product revenue net of $53.6 million, an increase from $42 million in Q1 FY26 and $49.2 million in Q2 FY25. Ex-factory bottle sales reached 2,929, representing a 26% quarter-over-quarter and 12% year-over-year increase. U.S. demand grew 8% quarter-over-quarter and 11% year-over-year to 2,986 bottles, primarily driven by the specialty distributor channel which saw 32% year-over-year growth. The company estimates inventory decreased by $1 million in Q2 FY26.
Alisertib Clinical Development Progress
The company is advancing two Phase II trials for its investigational drug alisertib: ALISCA-Breast1 (HER2-negative ER-positive breast cancer) and ALISCA-Lung1 (small cell lung cancer). The ALISCA-Breast1 protocol was amended to focus enrollment on 40mg and 50mg dose groups based on interim data suggesting potentially better activity in patients with specific biomarkers. For ALISCA-Lung1, the dose was further increased to 70mg BID, with 92 patients currently enrolled. Interim data from ALISCA-Lung1, including longer-term follow-up, is expected in Q4 FY26.
Future Alisertib Trials and Funding Outlook
Puma plans to initiate a second alisertib trial in small cell lung cancer, ALISCA-Lung2, in Q3 FY26, which will combine alisertib with paclitaxel. Initial data for ALISCA-Lung2 is anticipated in 2027. Management expressed confidence in the company's ability to fund potential Phase III trials for both alisertib indications in 2027, noting that they may stagger the trials if necessary to maintain positive net income, leveraging their newly debt-free status.
Financial Strength and Capital Allocation
Puma achieved a significant financial milestone by becoming debt-free in Q2 FY26, having made its final $11.1 million principal loan payment to Athyrium. The company reported $93.9 million in cash, cash equivalents, and marketable securities as of June 30, 2026. Management reiterated its commitment to maintaining positive net income and is actively evaluating in-licensing or acquiring commercial or development-stage drugs to diversify its portfolio and leverage existing infrastructure.
Marketing and Sales Strategy
Marketing initiatives are focused on increasing awareness of NERLYNX's dual indication in HER2-positive breast cancer (early and metastatic settings) and addressing unmet needs. The sales team prioritizes patients at higher risk of recurrence, clinical education, and patient resources to support persistence and compliance. Dose escalation remains an important commercial priority, with 73% of patients starting NERLYNX at a reduced dose.
Royalty Revenue and Generic Risk
Full-year royalty revenue guidance was slightly lowered due to the potential for generic versions of NERLYNX reaching a specific market share threshold in China in late 2026 or 2027. This threshold, if met, would trigger a reduction in the royalty rate payable to Puma under its sublicense agreement covering China.